You are invited to register to attend the upcoming webinar, Palbociclib (Ibrance) for metastatic ER+ breast cancer - NZ update, presented by Breast Cancer Foundation NZ (BCFNZ) with Dr Richard Finn (USA). Palbociclib (brand name Ibrance) is a new medicine for advanced ER+ breast cancer that has achieved significant results in high-profile clinical trials overseas. It’s not funded in New Zealand, but some Kiwis have been buying it off-shore, and there will soon be compassionate access for NZ patients that will make it potentially more affordable.
Webinar details
When: Monday March 19th, 2018
Time: 1.30-2.30pm
Duration: 60 minutes
Where: Online - wherever you like!
Presented by: Breast Cancer Foundation NZ
To regsiter, please click here.
Meet your panel
Dr Richard Finn, is associate professor of Medicine at the UCLA David Geffen School of Medicine. He led the PALOMA series of clinical trials for palbociclib and is considered one of the world’s foremost experts on this new drug.
BCFNZ also hope to have a NZ oncologist on the panel, but this is yet to be confirmed.
What will you get out of this session?
This session will give you a run-down on what palbociclib is, how it works and who for; where it sits among treatments for advanced ER+ breast cancer; opportunities in NZ for clinical trials and compassionate access to palbociclib; paying privately, and discussing palbociclib with your oncologist.
To register, please click here.
